New era of therapy for endocrine autoimmune disorders
Open Access
- 27 August 2020
- journal article
- review article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 92 (5), e12961
- https://doi.org/10.1111/sji.12961
Abstract
The new era of immune‐ and reconstitution therapy of autoimmune disorders is ongoing. However, endocrine autoimmune diseases comprise a group of elaborating pathologies where the development of new treatment strategies remains slow. Substitution of the missing hormones is still standard practice, taking care of the devastating symptoms but not the cause of disease. As our knowledge of the genetic contribution to the aetiology of endocrine disorders increases and early diagnostic tools are available, it is now possible to identify persons at risk before they acquire full‐blown disease. This review summarizes current knowledge and treatment of endocrine autoimmune disorders, focusing on type 1 diabetes, Addison’s disease, autoimmune thyroid diseases, and primary ovarian insufficiency. We explore which new therapies might be used in the different stages of the disease, and focus on legalized therapy, elaborate on the ongoing clinical studies for these diseases and the research front, before hypothesizing on the way ahead.Keywords
Funding Information
- Norges Forskningsråd
- Universitetet i Bergen
This publication has 249 references indexed in Scilit:
- IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasisSeminars in Immunology, 2012
- IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cellsProceedings of the National Academy of Sciences of the United States of America, 2012
- Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trialThe Lancet, 2011
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trialThe Lancet, 2011
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsThe Journal of Experimental Medicine, 2009
- C-Peptide Levels and Insulin Independence Following Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes MellitusJAMA, 2009
- Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapyBrain, Behavior, and Immunity, 2009
- Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic miceProceedings of the National Academy of Sciences of the United States of America, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008